- Neurotrope (NTRP) has dosed the first patient in Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease (AD). The study will be conducted in collaboration with the National Institutes of Health (NIH) under $2.7M grant to Neurotrope.
- The 100-subject study will evaluate Bryostatin-1 in the absence of Allergan/Abbvie's Namenda (memantine) for a six-month period, which will include two 11-week dosing cycles.
- The study will focus on assessing sustained cognitive benefit as measured by the Severe Impairment Battery (SIB) score.
- Previously completed Phase 2 study (NTRP101-202) showed Bryostatin-1 was well tolerated and showed early signals of cognitive benefit, including improvement of 5.0 points in SIB score compared to baseline in moderately severe cohort in the non-Namenda group. Second pilot trial (NTRP101-203) using the same treatment protocol showed a similar SIB improvement compared to baseline in moderately severe cohort.
- https://seekingalpha.com/news/3620132-neurotrope-initiates-long-term-alzheimers-study-bryostatin
Tuesday, October 6, 2020
Neurotrope initiates long-term Alzheimer's study with bryostatin
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.